Back HIV Treatment Search for a Cure

Search for a Cure

IAS 2017: VRC01 Antibody Can Delay But Not Prevent HIV Rebound

A broadly neutralizing antibody modestly delayed the resurgence of viral replication following interruption of antiviral therapy (ART) started during very early infection, but all study participants ultimately experienced viral rebound, according to results presented at the 9th International AIDS Society Conference on HIV Science (IAS 2017) last month in Paris.

alt

Read more:

IAS 2017: South African Child Has Controlled HIV Off Treatment for 8.5 Years

A 9-year-old South African child who was diagnosed with HIV infection at 1 month of age and received HIV treatment for 40 weeks during infancy has suppressed the virus without anti-HIV drugs for 8 and a half years, scientists reported this week at the 9th IAS Conference on HIV Science (IAS 2017) in Paris.

alt

Read more:

Coverage of the 2017 Conference on Retroviruses and Opportunistic Infections

HIVandHepatitis.com coverage of the 2017 Conference on Retroviruses and Opportunistic infections (CROI 2017), February 13-16, 2017, in Seattle.

Full coverage listing by topic

CROI website

4/16/17

alt

Coverage of the 2017 Harm Reduction International Conference

HIVand Hepatitis.com coverage of the 2017 Harm Reduction International Conference, May 14-17, 2017, in Montreal.

Full coverage listing

HR17 website

5/31/17

alt

CROI 2017: How Does Vedolizumab Antibody Therapy Lead to Sustained Viral Remission?

HIV and its monkey cousin SIV can carry the alpha-4 beta-7 integrin receptor in their outer envelope, which helps the virus enter gut cells during early infection, according to research presented at the recent Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle. This finding may help explain how an antibody against alpha-4 beta-7 produced sustained viral remission in monkeys.

alt

Read more: